Deep Inspiration Breath-hold Radiotherapy for Left-sided Breast Cancer
Deep Inspiration Breath-hold Radiotherapy for Left-sided Breast Cancer in Reducing Early Cardiac Injury: a Phase II Prospective Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Shu-Lian Wang
- Phone Number: 86-13366191993
- Email: wangsl@cicams.ac.cn
Study Locations
-
-
-
Beijing, China, 100021
- Recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Shu-Lian Wang
- Phone Number: 8610-87787659
- Email: wangsl@cicams.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Primary left-sided breast cancer post surgery
- Planning for adjuvant breast/chest wall +-RNI
Exclusion Criteria:
- History of cardiovascular disease
- Previous chest radiation
- Bilateral breast cancers
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Radiotherapy at free-breathing
breast/chest wall+-RNI 43.5Gy/15f/3w(tumor bed 49.5Gy/15f/3w) delivered at free-breathing
|
|
|
Radiotherapy at deep inspiration breath-hold
breast/chest wall+-RNI 43.5Gy/15f/3w(tumor bed 49.5Gy/15f/3w) delivered at deep inspiration breath-hold
|
Selective application of deep inspiration breath-hold technique
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of clinical or subclinical cardiac injury
Time Frame: two years
|
predefined cardiac events
|
two years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020-2-4023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.